- Home
- ZEPP vs IBIO Comparison
ZEPP vs IBIO Comparison
Compare ZEPP & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | IBIO |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 52.8M |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | IBIO |
|---|---|---|
| Price | $2.59 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 35.4K | ★ 800.7K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.23 | $0.73 |
| 52 Week High | $47.27 | $3.82 |
Technical Indicators
Market Signals| Indicator | ZEPP | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 14.85 | 25.28 |
| Support Level | N/A | N/A |
| Resistance Level | $5.57 | $1.52 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 20.62 | 0.85 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.
About IBIO iBio Inc.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.